Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Monday, 10 June 2013
- AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio AstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.
- Wednesday, 1 May 2013
- AstraZeneca and MedImmune are out in force at BIO 2013 This year team members from AstraZeneca and MedImmume business development attended over 500 partnering meetings at BIO in Chicago and took part in several high profile speaker panels.
- Wednesday, 24 April 2013
- Alchemia Announces Multi-Target Drug Discovery Collaboration with AstraZeneca on VAST Discovery Platform Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca PLC.